US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Neuroscience and Healthcare ETF

32.55

-0.3131-0.95%

Post-market: 32.55-0.0070-0.02%17:07 EDT

Volume:432

Turnover:14.10K

Market Cap:6.51M

PE:- -

High:32.56

Open:32.56

Low:32.55

Close:32.87

52wk High:43.01

52wk Low:27.40

Shares:200.00K

Float Shares:200.00K

Volume Ratio:0.31

T/O Rate:0.22%

Dividend:0.32

Dividend Rate:0.98%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Should Xenon’s Wider Q2 Losses to Fund Neurology Pipeline Require Action From Xenon (XENE) Investors?

Simply Wall St.

Jiangxi's Bold Strategy: Breaking Into Frontier Industries Without Coastal Advantages

Alkermes SVP, Chief Commercial Officer Christian Todd Nichols Sells 7,576 Shares for $374,301.99

Praxis Precision Medicines Could Be Approaching 'Perfect Trifecta,' Oppenheimer Says

MT Newswires Live

Praxis Precision Medicines, Inc. : Raymond James Raises Target Price to $945 from $765

THOMSON REUTERS

How Investors Are Reacting To Scholar Rock (SRRK) Dual Fill-Finish Readiness Amid Ongoing FDA Review

Simply Wall St.

Scholar Rock Grants Inducement Equity Awards for 51,947 Shares to 12 New Hires

Scholar Rock Reports New Employee Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS

Amex Halt Add Info Lst 43.010000

THOMSON REUTERS

Xenon Pharmaceuticals Director Steven Gannon Disposes of 10,000 Common Shares for $640,550

Scholar Rock Holding Price Target Raised to $63.00/Share from $56.00 by JP Morgan

BofA Securities Boosts Targets on Chinese CXO Players as Strong Biotech Funding Fuels R&D

Bank of America Securities Raises Targets for Chinese CXO Firms on Strong Biotech Funding

Alkermes Cuts Interest Spreads on $1.52 Billion Term Loan Facilities Via Credit Agreement Amendment

Alkermes - Enters Amendment No. 1 to Credit Agreement on August 12, 2026 - SEC Filing

THOMSON REUTERS

Alkermes - Amendment Reduces Interest Rate Spread Under Tla by 0.75% and Tlb by 0.50% - SEC Filing

THOMSON REUTERS

Jiangxi Party Chief Inspects Ganjiang New Area, Urges Accelerated Industry Transformation and New Growth Drivers

Yin Hong Inspects Ganjiang New Area: Striving to Seize New Industrial Frontiers, Forge New Growth Drivers, and Demonstrate Excellence

PICC P&C Issues China's First Invasive Brain-Computer Interface Surgery Accident Insurance

Dianthus Therapeutics SVP General Counsel Adam Veness Melepas Saham Senilai USD 2,21 Juta

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/IBRN/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IBRN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","market":"US","secType":"STK","nameCN":"iShares Neuroscience and Healthcare ETF","latestPrice":32.552,"timestamp":1790971200000,"preClose":32.8651,"halted":0,"volume":432,"hourTrading":{"tag":"盘后","latestPrice":32.545,"preClose":32.552,"latestTime":"17:07 EDT","volume":10,"amount":323.738,"timestamp":1790975268525,"change":-0.007,"changeRate":-0.000215,"amplitude":0},"delay":0,"changeRate":-0.00952682328670835,"floatShares":200000,"shares":200000,"eps":0,"marketStatus":"Market Closed","change":-0.3131,"latestTime":"10-02 16:00:00 EDT","open":32.561,"high":32.561,"low":32.545,"amount":14103,"amplitude":0.000487,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":32.8651,"sharesOutstanding":150000,"nav":32.771593,"aum":6554318.6,"dividendRate":0.00979,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":32.545,"preClose":32.552,"latestTime":"17:07 EDT","volume":10,"amount":323.738,"timestamp":1790975268525,"change":-0.007,"changeRate":-0.000215,"amplitude":0},"volumeRatio":0.3104039106268791,"impliedVol":0.0726,"impliedVolPercentile":0.3187},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","floatShares":200000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.3104039106268791,"shares":200000,"dividePrice":0.3187,"high":32.561,"amplitude":0.000487,"preClose":32.8651,"low":32.545,"week52Low":27.4025,"pbRate":"--","week52High":43.01,"institutionHeld":0,"latestPrice":32.552,"eps":0,"divideRate":0.00979,"volume":432,"delay":0,"ttmEps":0,"open":32.561,"prevYearClose":32.3193,"prevWeekClose":33.3342,"prevMonthClose":33.265,"prevQuarterClose":33.265,"fiveDayClose":33.3342,"twentyDayClose":39.3744,"sixtyDayClose":40.2891},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBRN\",params:#limit:5,,,undefined,":[{"date":"2025-12-16","symbol":"IBRN","amount":0.319807,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2024-12-17","symbol":"IBRN","amount":0.10114,"announcedDate":"2024-12-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2023-12-20","symbol":"IBRN","amount":0.006303,"announcedDate":"2023-12-19","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"},{"date":"2023-06-07","symbol":"IBRN","amount":0.008241,"announcedDate":"2023-05-12","type":"dividend","market":"US","newRecordDate":"2023-06-08","defaultRemindTime":1686144600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-06-13","payableDate":"2023-06-08","currency":"USD","dateTimestamp":1686110400000,"payDate":"2023-06-13"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBRN\",market:\"US\",,,undefined,":[{"executeDate":"2023-06-07","recordDate":"2023-06-08","paymentDate":"2023-06-13","value":0.008241,"currency":"USD"},{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.006303,"currency":"USD"},{"executeDate":"2024-12-17","recordDate":"2024-12-17","paymentDate":"2024-12-20","value":0.10114,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-19","value":0.319807,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBRN\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBRN\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660520417","title":"Should Xenon’s Wider Q2 Losses to Fund Neurology Pipeline Require Action From Xenon (XENE) Investors?","url":"https://stock-news.laohu8.com/highlight/detail?id=2660520417","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660520417?lang=en_us&edition=fundamental","pubTime":"2026-08-19 12:51","pubTimestamp":1787115071,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals Inc. recently reported second-quarter 2026 results, with net loss rising to US$110.74 million and basic loss per share from continuing operations at US$1.11, alongside a six‑month net loss of US$213.04 million and basic loss per share of US$2.28.\nThe widening losses compared with the same periods in 2025 give investors fresh insight into how Xenon is funding its ion-channel neurology pipeline ahead of key clinical and commercial milestones.\nWe will now examine how...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/should-xenons-wider-q2-losses-to-fund-neurology-pipeline-req","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/should-xenons-wider-q2-losses-to-fund-neurology-pipeline-req","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4211","BK4139","ISBC","IBRN","SBIO","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175067602","title":"Jiangxi's Bold Strategy: Breaking Into Frontier Industries Without Coastal Advantages","url":"https://stock-news.laohu8.com/highlight/detail?id=1175067602","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175067602?lang=en_us&edition=fundamental","pubTime":"2026-08-18 11:01","pubTimestamp":1787022066,"startTime":"0","endTime":"0","summary":"On August 7, 2026, the 15th Provincial Committee's 10th Plenary Session convened in Nanchang, followed by a collective study session of the Provincial Party Committee's Theoretical Learning Center...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROBT","IQM","UBOT","MNTL","IBRN","WDRN","RTOO","PBOT","HDRO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660430568","title":"Alkermes SVP, Chief Commercial Officer Christian Todd Nichols Sells 7,576 Shares for $374,301.99","url":"https://stock-news.laohu8.com/highlight/detail?id=2660430568","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660430568?lang=en_us&edition=fundamental","pubTime":"2026-08-18 06:54","pubTimestamp":1787007262,"startTime":"0","endTime":"0","summary":"Alkermes SVP, Chief Commercial Officer Christian Todd Nichols sells 7,576 shares for $374,301.99Alkermes SVP, Chief Commercial Officer Christian Todd Nichols sold 7,576 ordinary shares on Aug. 17, 202","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDLbv4Lk0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alkermes SVP, Chief Commercial Officer Christian Todd Nichols Sells 7,576 Shares for $374,301.99","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALKS","MEDX","PSCH","PSIL","IBRN","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660043669","title":"Praxis Precision Medicines Could Be Approaching 'Perfect Trifecta,' Oppenheimer Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2660043669","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660043669?lang=en_us&edition=fundamental","pubTime":"2026-08-17 23:21","pubTimestamp":1786980102,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines (PRAX) could be approaching an unprecedented regulatory stretch, with four potential approvals across three drugs within roughly 12 months, a potential \"perfect trifecta,\" O","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0889565916.HKD","IE0009355771.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU0320765992.SGD","PRAX","BK4127","IBRN","IE00B2B36J28.USD","OPY","LU0109394709.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660484118","title":"Praxis Precision Medicines, Inc. : Raymond James Raises Target Price to $945 from $765","url":"https://stock-news.laohu8.com/highlight/detail?id=2660484118","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660484118?lang=en_us&edition=fundamental","pubTime":"2026-08-17 19:10","pubTimestamp":1786965021,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nFWN44E0K1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBRN","IE0002141913.USD","PRAX","BK4139","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","IE0009355771.USD","LU0320765992.SGD","LU0109394709.USD","LU0889565916.HKD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659173150","title":"How Investors Are Reacting To Scholar Rock (SRRK) Dual Fill-Finish Readiness Amid Ongoing FDA Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2659173150","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659173150?lang=en_us&edition=fundamental","pubTime":"2026-08-15 21:21","pubTimestamp":1786800069,"startTime":"0","endTime":"0","summary":"In early August 2026, Scholar Rock Holding Corporation reported that its second-quarter net loss was US$109.9 million, slightly lower than a year earlier, while its six-month net loss widened to US$215.41 million and loss per share stayed broadly similar.\nAt the same time, the company highlighted that its apitegromab biologics license application for spinal muscular atrophy remains under active FDA review with two independent fill-finish facilities prepared to support potential approval and...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srrk/scholar-rock-holding/news/how-investors-are-reacting-to-scholar-rock-srrk-dual-fill-fi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srrk/scholar-rock-holding/news/how-investors-are-reacting-to-scholar-rock-srrk-dual-fill-fi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","IBRN","BK4588","LABU","BK4585","THNR","BK4211","SRRK","ISBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659129349","title":"Scholar Rock Grants Inducement Equity Awards for 51,947 Shares to 12 New Hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2659129349","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659129349?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:15","pubTimestamp":1786738521,"startTime":"0","endTime":"0","summary":"Scholar Rock grants inducement equity awards for 51,947 shares to 12 new hiresScholar Rock granted inducement equity awards covering 51,947 common shares to 12 newly hired employees under its 2022 Ind","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL6LXLYl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRRK","BK4139","IBRN","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659293951","title":"Scholar Rock Reports New Employee Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659293951","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659293951?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:15","pubTimestamp":1786738500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nTUA31SSFM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBRN","THNR","BK4139","SRRK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659714295","title":"Amex Halt Add Info Lst 43.010000","url":"https://stock-news.laohu8.com/highlight/detail?id=2659714295","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659714295?lang=en_us&edition=fundamental","pubTime":"2026-08-14 21:47","pubTimestamp":1786715258,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nAQN2MESOH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659160360","title":"Xenon Pharmaceuticals Director Steven Gannon Disposes of 10,000 Common Shares for $640,550","url":"https://stock-news.laohu8.com/highlight/detail?id=2659160360","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659160360?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:42","pubTimestamp":1786653738,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals director Steven Gannon disposes of 10,000 common shares for $640,550Xenon Pharmaceuticals director Steven Gannon sold 10,000 common shares on Aug. 11, 2026 at a weighted-average ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL1zKHrZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Xenon Pharmaceuticals Director Steven Gannon Disposes of 10,000 Common Shares for $640,550","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","BK4139","XENE","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659517165","title":"Scholar Rock Holding Price Target Raised to $63.00/Share from $56.00 by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2659517165","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659517165?lang=en_us&edition=fundamental","pubTime":"2026-08-13 23:19","pubTimestamp":1786634340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SRRK/analyst-ratings","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","THNR","SRRK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155684243","title":"BofA Securities Boosts Targets on Chinese CXO Players as Strong Biotech Funding Fuels R&D","url":"https://stock-news.laohu8.com/highlight/detail?id=1155684243","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155684243?lang=en_us&edition=fundamental","pubTime":"2026-08-13 12:50","pubTimestamp":1786596641,"startTime":"0","endTime":"0","summary":"BofA Securities has released a report indicating that the Chinese CXO sector is poised to benefit from robust biotech venture capital funding. The bank notes that strong financing in the first half...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1719994722.HKD","XBIX","LU0611395673.USD","BK0216","SURI","LU1046422090.SGD","LU1997245094.SGD","LU1969619763.USD","CXO","LU1251922891.USD","PSCH","LU2328871848.SGD","LU1997245177.USD","LU0708995583.HKD","LU0348766576.USD","BK1141","LU0348767384.USD","LU1770034418.SGD","LU0700851271.USD","LU1303224171.USD","BMED","LFSC","02359","FHLC","LU0456842615.SGD","BBC","PSIL","IE00B5MMRT66.SGD","APXH","LU0320764599.SGD","603259","MEDI","LU2495084118.USD","LU2242644610.SGD","LU2045819591.USD","LU2125910500.SGD","161027","IE00BPRC5H50.USD","IBRN","LU1997244956.HKD","LU0052750758.USD","LU2488822045.USD","LU1979443071.USD","BK1583","SMCO","BK1576","LU1808992512.USD","IE00B543WZ88.USD","LU1934453819.USD","WX","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111112440","title":"Bank of America Securities Raises Targets for Chinese CXO Firms on Strong Biotech Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=1111112440","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111112440?lang=en_us&edition=fundamental","pubTime":"2026-08-13 10:35","pubTimestamp":1786588544,"startTime":"0","endTime":"0","summary":"A report from Bank of America Securities indicates that Chinese CRO/CDMO companies are poised to benefit from robust first-half funding in the global and Chinese biotech sectors, along with active...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348766576.USD","LU2242644610.SGD","603259","LU1997244956.HKD","LU1880383366.USD","LU1242518931.SGD","LU0128526141.USD","LU2328871848.SGD","IE00B5MMRT66.SGD","BK1576","LU0819121731.USD","IDNA","CXO","BK1521","LU0051755006.USD","WX","LU0516423174.USD","SG9999002562.SGD","LU0348767384.USD","LU0039217434.USD","IE00BPRC5H50.USD","LU1242518857.USD","BK1141","LU3063872942.SGD","LU0516423091.SGD","KURE","LU0307460666.USD","FHLC","LU0456846285.SGD","LU0348735423.USD","IE00B543WZ88.USD","LU1934453819.USD","LU0516422952.EUR","LU0708995583.HKD","XBIX","PSIL","LU0611395673.USD","LU2045819591.USD","03759","LU0417516902.SGD","LU0456827905.SGD","PSCH","LU1997245094.SGD","LU0052750758.USD","LU1770034418.SGD","LU0979878070.USD","LU0572944931.SGD","SURI","LU2495084118.USD","LU1979443071.USD","BMED","LU1719994722.HKD","MEDI","IBRN","LU2125910500.SGD","SMCO","LU1969619763.USD","LU1997245177.USD","LU0823426308.USD","BBC","LFSC","02359","BK1610","IE00B0JY6N72.USD","LU0359201612.USD","LU1808992512.USD","LU0140636845.USD","LU0326950275.SGD","SG9999002463.SGD","LU2488822045.USD","LU0181495838.USD","161027","LU1303224171.USD","LU0320764599.SGD","BK1583","BK0216","LU1046422090.SGD","LU0043850808.USD","LU1720050803.USD","LU1794554557.SGD","BK1589","LU0417516738.SGD","LU1251922891.USD","LU0348825331.USD","02269","LU0327786744.USD","APXH","LU0588546209.SGD","LU0456842615.SGD","LU0516422366.SGD","LU0856984785.SGD","LU0516422440.USD","LU2039709279.SGD","LU0700851271.USD","LU0823426480.USD","LU0359202008.SGD","LU0029874061.USD","LU1688375341.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658906555","title":"Alkermes Cuts Interest Spreads on $1.52 Billion Term Loan Facilities Via Credit Agreement Amendment","url":"https://stock-news.laohu8.com/highlight/detail?id=2658906555","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658906555?lang=en_us&edition=fundamental","pubTime":"2026-08-12 23:19","pubTimestamp":1786547988,"startTime":"0","endTime":"0","summary":"Alkermes cuts interest spreads on $1.52 billion term loan facilities via credit agreement amendmentAlkermes entered an amendment on Aug. 12, 2026 to its Feb. 12, 2026 credit agreement with JPMorgan Chase Bank.The deal covers senior secured term loan A of USD 745.31 million, due Feb. 12, 2031, and term loan B of USD 773.06 million, due Aug. 12, 2031.The amendment cuts the interest spread by 0.75% on the term loan A facility, 0.5% on the term loan B facility.Term loan A now prices at Term SOFR plus 1.75%-2.25%, or base rate plus 0.75%-1.25%, based on secured net leverage.Term loan B now prices at Term SOFR plus 2.25%, or base rate plus 1.25%.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alkermes plc published the original content used t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL3L5Jbs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FTXO","LU2237443622.USD","JPO","JPX","IE00BYXW3230.USD","PSIL","LU1974910355.USD","PSCH","IXG","LU2462157665.USD","LU1363072403.SGD","LU2054465674.USD","LU2357305700.SGD","MEDX","TRUF","LU2106854487.HKD","JPMO","LU1551013425.SGD","FNCL","LU1162221912.USD","LU0265550946.USD","UYG","LU2505996681.GBP","ALKS","LU0320765489.SGD","LU0211326755.USD","XLF","IYG","LU0106261372.USD","LU1720051017.SGD","LU2023250843.SGD","LU1496350502.SGD","LU0496365809.HKD","LU2552382132.HKD","LU1629891620.HKD","FBT","LU2456880835.USD","LU0345770993.USD","LU0234572021.USD","IE00BZ1G4Q59.USD","LU2552382215.SGD","LU0211331839.USD","IYF","KBWB","VFH","TFNS","LU0208291251.USD","LU0320765646.SGD","IBRN","LU1116320901.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658908840","title":"Alkermes - Enters Amendment No. 1 to Credit Agreement on August 12, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2658908840","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658908840?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:27","pubTimestamp":1786541257,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4491BU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSIL","PSCH","IBRN","FBT","ALKS","MEDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658908808","title":"Alkermes - Amendment Reduces Interest Rate Spread Under Tla by 0.75% and Tlb by 0.50% - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2658908808","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658908808?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:27","pubTimestamp":1786541257,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4491BU:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MEDX","IBRN","PSIL","PSCH","BK4139","ALKS","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107826889","title":"Jiangxi Party Chief Inspects Ganjiang New Area, Urges Accelerated Industry Transformation and New Growth Drivers","url":"https://stock-news.laohu8.com/highlight/detail?id=1107826889","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107826889?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:40","pubTimestamp":1786538436,"startTime":"0","endTime":"0","summary":"A provincial official, Yin Hong, visited the Ganjiang New Area on August 12, emphasizing the need to fully implement the spirit of the 15th Provincial Committee's 10th Plenary Session. He urged the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","MNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178440125","title":"Yin Hong Inspects Ganjiang New Area: Striving to Seize New Industrial Frontiers, Forge New Growth Drivers, and Demonstrate Excellence","url":"https://stock-news.laohu8.com/highlight/detail?id=1178440125","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178440125?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:01","pubTimestamp":1786536063,"startTime":"0","endTime":"0","summary":"On August 12, Yin Hong, Secretary of the Provincial Party Committee, conducted an in-depth inspection of the Ganjiang New Area. He emphasized the need to fully implement the spirit of the 15th...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","MNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136280436","title":"PICC P&C Issues China's First Invasive Brain-Computer Interface Surgery Accident Insurance","url":"https://stock-news.laohu8.com/highlight/detail?id=1136280436","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136280436?lang=en_us&edition=fundamental","pubTime":"2026-08-12 11:08","pubTimestamp":1786504105,"startTime":"0","endTime":"0","summary":"On August 12, PICC Property and Casualty Company Limited, a subsidiary of People's Insurance Company (Group) of China Limited (01339), announced it has underwritten the country's first invasive...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNTL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658468579","title":"Dianthus Therapeutics SVP General Counsel Adam Veness Melepas Saham Senilai USD 2,21 Juta","url":"https://stock-news.laohu8.com/highlight/detail?id=2658468579","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658468579?lang=en_us&edition=fundamental","pubTime":"2026-08-12 05:09","pubTimestamp":1786482556,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics SVP General Counsel Adam Veness melepas saham senilai USD 2,21 jutaSVP, General Counsel dan Secretary Adam M Veness melepas seluruh kepemilikan saham biasa Dianthus Therapeutics.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL4W8dyv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Dianthus Therapeutics SVP General Counsel Adam Veness Melepas Saham Senilai USD 2,21 Juta","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNTH","IBRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}]}}